Skip to main content
INSM logo

Insmed Incorporated (INSM) Stock: Price, Forecast & Analyst Target

Insmed Incorporated (INSM) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $119.80 (-1.69%), as of the Nov 18, 2026 trading session; market cap $26.3B.

Educational signal · not a buy or sell recommendation · How to read this

$119.80 −$2.06 (-1.69%) Market Cap $26.3B

Insmed Incorporated · INSM · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-12: Insmed is a commercial rare-lung-disease biopharma built around ARIKAYCE while expanding through BRINSUPRI and TPIP. What matters is whether rapidly rising commercial revenue can outrun launch and clinical investment before liquidity erodes.

Price as of Nov 18, 2026

Key Statistics

31 of 100

MoonshotScore v2 · Insmed (INSM)

Weak
Business Quality Average (48)
Financial Safety Strained (29)
Valuation Full (41)
Growth Durability Growing (69)
Momentum Rising (61)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Durable growth, but a strained balance sheet and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Rising.

  • quarterly revenue $142M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 7.58 · Piotroski F 4

Holding back: balance-sheet strain

Helping: durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for INSM (57 recorded, newest six shown)
RecordedScoreBand
30Weak
30Weak
30Weak
30Weak
31Weak
31Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$119.80
Change on the day-1.69%
52-week range$90.39–$212.75
Market capitalisation$26.3B—
Price / earnings (trailing)244.75
Shares traded on the day1.94M
Beta (volatility vs the S&P 500)0.81

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $93, high $208, latest $120. $208 $93 high $208 Oct 17, 2025 Nov 18, 2026 · $120 $166Oct 17, 2025$190Oct 31, 2025$193Nov 14, 2025$208Nov 28, 2025$197Dec 12, 2025$178Dec 26, 2025$176Jan 9, 2026$156Jan 23, 2026$150Feb 6, 2026$165Feb 20, 2026$140Mar 6, 2026$136Mar 20, 2026$162Apr 2, 2026$144Apr 17, 2026$133May 1, 2026$109May 15, 2026$107May 29, 2026$98Jun 12, 2026$103Jun 26, 2026$116Jul 10, 2026$107Jul 24, 2026$131Aug 7, 2026$126Aug 21, 2026$126Sep 4, 2026$120Sep 18, 2026$111Oct 2, 2026$96Oct 16, 2026$113Oct 30, 2026$121Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Insmed (INSM): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Weak
Valuation Neutral
Growth Durability Moderate
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Insmed (INSM), and what does it report?

Short answer · as of

Insmed is not a development-only biotechnology company. It markets ARIKAYCE as part of an antibacterial regimen for adults with MAC lung disease, while BRINSUPRI and the inhaled TPIP program broaden its exposure to bronchiectasis and other rare lung disorders.

Revenue is reported within an aggregate segment rather than as separate product businesses. The headline income statement therefore measures the combined commercial operation, while research spending captures an unusually active pipeline alongside marketed therapies.

2 · Latest results

What do the latest results show for Insmed (INSM)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $142M.

Revenue accelerated sharply and reached the high point of the reported quarterly series. Gross profit rose with it, the operating loss almost disappeared, and the net loss contracted dramatically; reported revenue and earnings also surpassed market estimates. Operating cash use improved but remained negative, so accounting progress has not yet become cash generation.

Management links the commercial outlook to BRINSUPRI patient starts and expects net realization from the product to remain within its updated range. At the same time, it plans heavier spending on the BRINSUPRI launch, TPIP clinical programs, consumer promotion, and commercial infrastructure in Japan, creating a direct test of whether adoption can scale faster than the supporting cost base.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$142M-$370M-$1.75 (diluted)
Q4 FY2025$264M-$328M-$1.54 (diluted)
Q1 FY2026$306M-$164M-$0.76 (diluted)
Q2 FY2026$425M-$13M-$0.06 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Insmed (INSM)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Cash and short-term investments exceed total debt, and the liquidity ratios indicate substantial near-term coverage. The balance carries no separately classified long-term investments, so the readily available pool is the relevant funding base.

That cushion is being consumed. Operating cash flow has remained negative throughout the displayed series, cash finished below its opening level across the measured window, and the internally calculated runway is finite. Management believes current resources can carry the business through cash-flow positivity without another capital raise, but that claim depends on the recent earnings improvement persisting while launch and research spending expand.

Valuation adds execution pressure: net cash is small relative to market value, while sales and book multiples are elevated despite negative trailing profitability. The wide range of longer-horizon revenue estimates shows how sensitive the narrative remains to commercial uptake and pipeline delivery.

Data-derived red flags

  • Negative return on equity (-72.5%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 244.75 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Insmed (INSM)?

Short answer · as of

Current published price targets run low $154.00 · high $235.00 · consensus $191.06 · median $193.50 against a quoted price of $119.80 (as of Nov 18, 2026).

BRINSUPRI patient starts, realized revenue after concessions, and sequential revenue growth are the most direct commercial checks. The scheduled earnings release also provides a clear comparison against market expectations after recent results exceeded revenue and earnings estimates.

Cash use deserves equal attention. Watch whether operating cash outflow continues to narrow even as Insmed funds branded promotion, Japanese commercial infrastructure, and TPIP development; renewed deterioration would weaken management’s assertion that existing resources can bridge the company to cash generation.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Oct 30, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Insmed compare with its peers?

Short answer

Insmed's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Insmed sits between development-stage biotechnology and mature specialty pharmaceuticals. ARIKAYCE already gives it a commercial rare-lung-disease franchise, while BRINSUPRI commercialization and TPIP development preserve the clinical and launch risk normally associated with a pipeline company.

Its aggregate segment presentation also differs from businesses that disclose mature product franchises separately. Investors must judge the commercial transition through consolidated revenue, margins, spending, and cash use rather than clean product-level profit lines.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$941.25 Nov 18, 2026$59.2B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Named competitor$278.35 Nov 18, 2026$64.3B88 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Named competitor$177.33 Nov 18, 2026$50.0B83 5-pillar Nov 18, 2026
Humana Inc. (HUM) Named competitor$385.78 Nov 18, 2026$46.3B79 5-pillar Nov 18, 2026
Haleon plc (HLN) Named competitor$9.08 Nov 18, 2026$39.8B75 5-pillar Nov 18, 2026
Takeda Pharmaceutical Company Limited (TAK) Named competitor$21.27 Nov 18, 2026$68.0B73 5-pillar Nov 18, 2026
Insmed (INSM) — this page$119.80$26.3B31

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$154.00 – $235.00
Consensus target
$191.06
Median target
$193.50

Consensus record · Captured .

Measured against a quoted price of $119.80 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 19, 2026

Transactions
55
Identified insiders
10
Purchases
0
Sales
25
Other transactions
30

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held INSM in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 20262.79%$124.72MTrimmed −23.3% shares
Bridgewater AssociatesFounded by Ray DalioQ3 20260.19%$44.07MTrimmed −15.2% shares
Duquesne Family OfficeStanley DruckenmillerQ3 20261.40%$62.78MCall options · Trimmed −59.3% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Insmed (INSM)?

Read these with our analysis →

What Investors Ask About Insmed (INSM) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How does ARIKAYCE make Insmed different from a development-stage biotech?

ARIKAYCE gives Insmed an existing commercial business serving adults with MAC lung disease, so reported revenue reflects marketed therapy rather than only licensing or research activity. Pipeline execution still matters because BRINSUPRI and TPIP carry much of the expansion opportunity.

Why are BRINSUPRI patient starts important for Insmed?

Patient starts are management’s stated bridge between launch activity and higher revenue. Their value depends on sustained treatment demand and the net revenue retained after concessions.

What does TPIP spending mean for Insmed’s cash profile?

TPIP adds clinical investment while the company is still using cash in operations. Progress can expand Insmed’s rare-lung pipeline, but spending on those programs competes with BRINSUPRI commercialization for the same liquidity pool.

Can Insmed fund BRINSUPRI commercialization without new capital?

Management believes existing resources can fund the business through cash-flow positivity without another raise, and liquid assets currently exceed debt. Continued negative operating cash flow and planned commercial investment make that conclusion dependent on revenue scaling and cash use improving together.

What is the INSM stock price today?

The last price recorded for Insmed Incorporated (INSM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the INSM price target?

The analyst consensus price target for Insmed Incorporated (INSM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 27 figures on this page — 1 from SEC filings and earnings calls, 22 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 1. What is Insmed (INSM), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Insmed (INSM)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Insmed (INSM)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash runway cross-check (ours); Trailing twelve-month ratio set; Cash against market value; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts
  • 4. What should you watch next at Insmed (INSM)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Management outlook — dated call excerpts
  • 5. How does Insmed compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Management outlook — dated call excerpts
  • FAQ: How does ARIKAYCE make Insmed different from a development-stage biotech?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: Why are BRINSUPRI patient starts important for Insmed?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • FAQ: What does TPIP spending mean for Insmed’s cash profile?: Business description; Operating cash flow by quarter (USD millions); Cash, investments and debt; Management outlook — dated call excerpts
  • FAQ: Can Insmed fund BRINSUPRI commercialization without new capital?: Cash, investments and debt; Cash runway cross-check (ours); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.